Undetected Toxicity Risk in Pharmacogenetic Testing for Dihydropyrimidine Dehydrogenase

Fluoropyrimidines, the mainstay agents for the treatment of colorectal cancer, alone or as a part of combination therapies, cause severe adverse reactions in about 10%–30% of patients. Dihydropyrimidine dehydrogenase (DPD), a key enzyme in the catabolism of 5-fluorouracil, has been intensively inves...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Int J Mol Sci
Main Authors: Falvella, Felicia Stefania, Caporale, Marta, Cheli, Stefania, Martinetti, Antonia, Berenato, Rosa, Maggi, Claudia, Niger, Monica, Ricchini, Francesca, Bossi, Ilaria, Di Bartolomeo, Maria, Sottotetti, Elisa, Bernardi, Francesca Futura, de Braud, Filippo, Clementi, Emilio, Pietrantonio, Filippo
Formato: Artigo
Idioma:Inglês
Publicado: MDPI 2015
Assuntos:
Review
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4425114/
https://ncbi.nlm.nih.gov/pubmed/25906475
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms16048884
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares